PPHN
6
0
1
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
16.7%
1 terminated out of 6 trials
66.7%
-19.8% vs benchmark
17%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)
Vardenafil Vs Sildenafil for the Treatment of Pulmonary Hypertension of the Newborn
Predictors of Inhaled Nitric Oxide Responsiveness in Patients With PPHN
Evaluation of the Prevalence of Persistent Pulmonary Hypertension in Neonates
Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN)
Nebulized MgSO4 in Persistent Pulmonary Hypertension of Newborn